Multiple Sclerosis Comprehensive Update
This session is one of four sessions that make up the full course "Multiple Sclerosis Comprehensive Update: Overview of Clinical Management, Therapeutic Strategies and Research Trends." Learners have the option of registering for the full course or registering for the four sessions individually.
-
Disclosure Policy
All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The following planners, speakers, and content reviewers have reported relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated:
NAME COMPANY RELATIONSHIP Course Planners Tanuja Chitnis, MD, MA, FAAN Novartis Advisory Board/Committee, Consultant Sanofi Advisory Board/Committee, Consultant Sanofi Research Support Novartis Research Support Octave Research Support Roche Genentech Consultant I-Mab Biopharma Research Support Roche Genentech Research Support Tiziana Life Sciences Research Support, Consultant Maria Houtchens, MD, MSc Biogen Research Support, Consultant Genzyme Research Support Serono Consultant Roche Research Support, Advisory Board/Committee Novartis Research Support Course Faculty Shamik Bhattacharyya, MD Alexion Pharmaceuticals Research Support Michael Levy, MD, PhD Alexion Research Support, Consultant Genetech Consultant, Research Support Horizon Consultant Horizon Research Support UCB Investigator Sanofi Investigator Christopher Severson, MD Novartis Advisory Board/Committee Biogen Advisory Board/Committee Roche/Genentech Advisory Board/Committee Sanofi/Genzyme Advisory Board/Committee Jonathan Zurawksi, MD Novartis Pharmaceutical Research Support All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.